跳轉至內容
Merck
  • High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada.

High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada.

Antimicrobial agents and chemotherapy (2010-01-06)
Gisele Peirano, David Richardson, Jana Nigrin, Allison McGeer, Vivian Loo, Baldwin Toye, Michelle Alfa, Colette Pienaar, Pamela Kibsey, Johann D D Pitout
摘要

Phenotypic and genotypic methods were used to characterize extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli isolated in 2007 from 11 different Canadian medical centers. Of the 209 ESBL-producing E. coli isolates tested, 148 (71%) produced CTX-M-15, 17 (8%) produced CTX-M-14, 5 (2%) produced CTX-M-3, and 1 produced CTX-M-27. Overall, 96 (46%) of the ESBL producers belonged to clonal complex ST131, with the highest prevalence in Brampton, Calgary, and Winnipeg. ST131 is an important cause of community onset urinary tract infections due to ESBL-producing E. coli across Canada.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
环丙沙星, ≥98% (HPLC)
Sigma-Aldrich
呋喃妥因, 98.0-102.0% (EP, UV)
Supelco
环丙沙星, VETRANAL®, analytical standard
Supelco
呋喃妥因, VETRANAL®, analytical standard